TEVAGRASTIM ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-002228-28-IT (EUCTR) | 01/09/2014 | 12/06/2014 | STEMALS-II | A double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis - STEMALS-II | Amyotrophic lateral sclerosis (ALS) is a severe progressive neurological disorder characterized by a selective degeneration of spinal, bulbar, and cortical motor neurons.;Therapeutic area: Not possible to specify | Trade Name: TEVAGRASTIM Product Name: filgrastim Trade Name: MANNITOLO 18% LDB Product Name: MANNITOLO 18% Trade Name: PERFALGAN Product Name: PARACETAMOLO | Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 2 | Italy |